| Literature DB >> 26775146 |
Fabian Higel1, Andreas Seidl2, Fritz Sörgel3, Wolfgang Friess4.
Abstract
Monoclonal antibody and Fc fusion protein drugs are complex heterogeneous mixtures of numerous different protein variants and modifications. N-glycosylation as one of the most complex post-translational modification influences the structural characteristics of the antibodies Fc part thereby potentially modulating effector function and pharmacokinetics. Several investigations on the relationship between N-glycosylation and pharmacokinetics have been published. However, this structure-function relationship is not fully understood. In this review potential alterations with focus on N-glycosylation of mAbs and Fc fusion proteins and the possible effects on the pharmacokinetics are reviewed and the current understandings of the underlying mechanisms are described.Entities:
Keywords: Fusion protein; Glyco-engineering; Monoclonal antibody; N-glycosylation; Pharmacokinetics
Mesh:
Substances:
Year: 2016 PMID: 26775146 DOI: 10.1016/j.ejpb.2016.01.005
Source DB: PubMed Journal: Eur J Pharm Biopharm ISSN: 0939-6411 Impact factor: 5.571